Pharmaceutical Articles

• “Quasi-Experimental” Study Data Does Not Support Conclusion that FDA Warnings May Have Led to More Suicide Attempts
  Baum, Hedlund, Aristei & Goldman
  June 20, 2014

• 60 Minutes Report: Antidepressants — The Emperor Has No Clothes
  Baum, Hedlund, Aristei & Goldman
  March 8, 2012

• Challenging Medical Ghostwriting in US Courts
  PLOS Medicine
  January 24, 2012

• Reason Magazine Perpetuates False Information About Safety and Efficacy of Antidepressants
  Baum, Hedlund, Aristei & Goldman
  September 30, 2011

• Levine To Mensing — A Journey From The Sublime To The Ridiculous
  LexisNexis® Mealey’s™ Emerging Drugs & Devices, Volume 16, Issue #16
  August 18, 2011

• The Exclusionary Rule in Strict Liability Cases: A Defect in the Law
  American Association for Justice – Products Liability Newsletter
  Vol. 15, No. 1, Fall 2010

• Outsmarting the “Learned-intermediary Doctrine” Defense Against Big Pharma
  The Advocate
  February 2010, pg 62

• Preemption’s Requiem in the Wake of WYETH V. LEVINE
  Published in LexisNexis® Mealey’s™ Emerging Drugs & Devices
  Volume 14, Issue#10
  May 21, 2009

• Complete Tort Immunity For Drug Manufacturers Is Bad For The Public Health:
  A Commentary On Colacicco v. Apotex And Other Recent Preemption Decisions
  Mealey’s Litigation Report: Antidepressant Report
  May 2008

• Defense Medical Exams (DMEs),
  Practical Ways to Limit Physical and Mental Examinations
  FORUM, Consumer Attorneys of California
  January/February 2008

• Antidepressants During Pregnancy: The Drug Companies Tip the Scale
  Law.com
  February 2007

• Focus on Facts to Defeat Preemption
  TRIAL
  March 1, 2007

• Preemption and Negligent Pharmacovigilance
  ATLA Education Seminar
  Protecting the Public: Pharmaceutical and Medical Device Litigation
  November 2006

• Discovery of FDA and Other Regulatory Agency Evidence
  ATLA Education Reference Materials
  ATLA 2006 Annual Convention

• Preamble To FDA Final Rule: FDA s Latest Effort To Immunize Drug Manufacturers From Tort Liability At The Expense of Consumer Safety
  Mealey’s Emerging Drugs & Devices
  February 2006
  Mealey’s Litigation Report: Antidepressant Report
  February 2006

• Preemption and the FDA — Politics as Usual
  ATLA Winter Convention Reference Materials, Track II:
  Protecting the Public: Pharmaceutical and Medical Device Litigation
  February 2006

• The FDA, Drug Manufacturers, And SSRI Preemption: A Match Made In Heaven?
  Mealey’s Litigation Report Antidepressant Drugs
  November 2005

• What Happened to the FDA?
  Harris Martin’s Columns: Drugs & Supplements
  July 2005

• Internet Disclaimers: Do they waive the attorney-client privilege protection?
  ABA Conference “The Future of Class Action Litigation in America”

• The FDA’s Dilemma: Safety Failures, Public Scrutiny, and Industry Influence
  ATLA Education Reference Materials
  2005

• A Cure Worse Than the Disease
  “Recent FDA actions and newly disclosed research on the link between antidepressants and suicide – especially among young people – are strengthening plaintiffs’ claims against drug makers”
  TRIAL
  2005

• The Antidepressant Controversy: The Growth Of A New Area Of Litigation
  Mealey’s Litigation Report Antidepressant Drugs
  2004

• The Fox in the Chicken Coop
  FDA’s Recent Intervention in Pharmaceutical Litigation
  ATLA Education
  2003

• Biting the Magic Bullet: A Look at the SSRI Litigation
  Harris Martin’s Columns: Drugs & Supplements
  August 2002